PET/CT is a "more effective" way to evaluate radioimmunotherapy in non-Hodgkin lymphoma patients, says a news release from the University of Southern California. "Using this relatively novel hybrid imaging means that some patients will only require a one-day treatment of radioimmunotherapy instead of several rounds of chemotherapy," said one of the researchers.

Full Story:
Medical News Today

Related Summaries